Jiangbo Pharmaceuticals woos pharma distributor Xinkangqi Medical
This article was originally published in Scrip
Executive Summary
Jiangbo Pharmaceuticals, the NASDAQ-quoted Chinese pharma company, has unveiled plans to acquire Xinkangqi Medical, a regional wholesale drug distributor in Shandong Province, the home to 94 million people. A final price will be determined once Jiangbo has completed its due diligence, which is expected to conclude within three months. Jiangbo will retain Xinkangqi's current employees and management team when the acquisition closes by the end of September 2011.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.